Navigation Links
Latest Drug Sales Data: Loss of Patent Protection Has Significant Effect, According to Drugs.com
Date:8/21/2012

NEW YORK, Aug. 21, 2012 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released second quarter 2012 U.S. prescription sales data for the top 100 drugs.

Proton-pump inhibitors, antipsychotics, asthma therapeutics and statins remain the top-selling categories. Plavix and Seroquel dipped in the second quarter due to loss of patent protection. Other top brands such as Singulair, Actos and Diovan are also due to be impacted by year's end.

 

Top Five Drugs by Sales, Q2 2012Drug Name

Sales ($000)

% Change (previous quarter)Nexium

$1,380,413

-1.12%Abilify

$1,379,149

2.91%Singulair

$1,287,806

4.01%Advair Diskus

$1,124,985

-1.25%Crestor

$1,124,702

0.61%AstraZeneca's Nexium claims the top spot with over $1.38 billion in sales, overtaking Plavix, which dropped to ninth. Otsuka's Abilify exceeded sales of $1.37 billion in a close race with Nexium. Merck's top-selling asthma and allergy brand Singulair finished the quarter strongly with over $1.28 billion in sales. However, competition is on the horizon with the first generic versions of Singulair (montelukast) approved by the FDA in early August.

 

Top Five Sales Gains, Q2 2012

Drug Name

Gain ($000)

% Change (previous quarter)escitalopram

$206,199

+98.11%Humira

$87,515

+9.43%Epogen

$65,278

+13.33%Rituxan

$62,543

+8.26%Enbrel

$57,984

+6.51%Escitalopram, the generic version of Forest's Lexapro, makes the largest gain, almost doubling from the previous quarter to close with $416 million in sales.

 

Top Five Sales Losses, Q2 2012

Drug Name

Loss ($000)

% Change (previous quarter)Seroquel

-$1,001,283

-86.23%Plavix

-$686,059

-42.33%Lipitor

-$261,418

-31.09%atorvastatin

-$168,400

-17.68%budesonide

-$64,282

-24.99%While the extended release formulation of Seroquel (Seroquel XR) remains patent protected until 2017, the immediate release version of Seroquel claims the top loss in Q2.

"Medicines appearing at the top of the sales data for the second quarter show a strong brand presence, reinforcing the impact of research and development across multiple disease states," said Philip Thornton, CEO of Drugs.com. "However, as many top brands face patent expiration over the next few years, a reduction in sales of affected medicines will be inevitable - with each expiration contributing to the phenomenon colloquially referred to as the 'patent cliff.'"

Dollar losses in Q2 2012 are unprecedented. Seroquel forfeits close to 86 percent, or over $1 billion in sales and plummets 95 spots in sales ranking due to loss of patent protection. Lipitor and its generic counterpart atorvastatin, which posted the number-one sales gain in Q1 2012, both close the quarter with sales losses.

Detailed data on the top 100 drugs can be accessed at:
http://www.drugs.com/stats/top100/sales

About Drugs.comDrugs.com is the leading online drug information resource with over seven million unique visitors per month (ComScore, June 2012). Providing free, independent, peer-reviewed, and up-to-date information at both consumer and professional levels, Drugs.com empowers patients and caregivers to take charge of their health and be more informed than ever before. The site includes many interactive tools and mobile apps to assist consumers, healthcare professionals and researchers, such as personal medication records, a drug interaction checker, pill identification wizard, symptom checker, pharma sales statistics and more.

For more information, visit: http://www.drugs.com.

Media Inquiries:
Drugs.com Press Officer
press@drugs.com
(718) 395 2473

 

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com


'/>"/>
SOURCE Drugs.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Siemens Unveils New Solutions and Latest Innovations at AACC 2012
2. Prostate Cancer Center of New Jersey the Latest Center to Achieve High Honor of ACR-ASTRO Accreditation
3. Elekta to Demonstrate Latest MOSAIQ OIS Innovations for Oncology Practices at 2012 ASCO Annual Meeting
4. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
5. Star Scientific, Inc. Files Second-Quarter Financial Report (Net Sales and Gross Profits Continue to Increase) and Updates Research and Marketing Activities
6. Sales Force Effectiveness in Pharmaceuticals - Targeted Sales Models such as Enhanced Key Account Management (KAM) and Closed-Loop Marketing (CLM) Strategies Drives Sales Force Efficiency
7. Block Engineering Partners with SKAE and Pembroke for Quantum Cascade Laser Instrument Sales
8. Misonix Adds 6 Spine Sales Agencies In The U.S.
9. New Medical Device Market Research Reports Tracking over $9.5 Billion of Annual Sales Volume Now Available from GII
10. Shire Second Quarter Product Sales Up 16%
11. Heart IT Announces Record Sales for 1st Half of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare ... CPR training aide "cprCUBE" on Kickstarter. The device will ... during cardiac arrests with better efficiency compared to the ... offers real-time feedback on efficacy of the compression for ... campaign has a goal to raise $5,000. ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):